You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
AstraZeneca
McKinsey
Colorcon
Express Scripts

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CANNABIDIOL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Cannabidiol

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT04423341 Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Enrolling by invitation Benign Essential Blepharospasm Research Foundation Phase 2/Phase 3 2020-05-20 The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Additionally, patients will undergo EEG monitoring via a Blink-EEG protocol for objective data measurements of changes induced by CBD in Blepharospasm patients. Independent second measures will be of blink kinematic analysis of review of video recording. Results would also be correlated with the Blepharospasm Severity Disability Index, Modified CDQ-24 scale and Jankovic Rating Scale. To assess any change in anxiety that might be relevant to therapeutic effect, the anxiety scale GAD-7 survey will also be administered and correlated with the results. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone.
OTC NCT04423341 Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Enrolling by invitation GW Pharmaceuticals Ltd. Phase 2/Phase 3 2020-05-20 The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Additionally, patients will undergo EEG monitoring via a Blink-EEG protocol for objective data measurements of changes induced by CBD in Blepharospasm patients. Independent second measures will be of blink kinematic analysis of review of video recording. Results would also be correlated with the Blepharospasm Severity Disability Index, Modified CDQ-24 scale and Jankovic Rating Scale. To assess any change in anxiety that might be relevant to therapeutic effect, the anxiety scale GAD-7 survey will also be administered and correlated with the results. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone.
OTC NCT04423341 Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Enrolling by invitation Smith-Kettlewell Eye Research Institute Phase 2/Phase 3 2020-05-20 The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Additionally, patients will undergo EEG monitoring via a Blink-EEG protocol for objective data measurements of changes induced by CBD in Blepharospasm patients. Independent second measures will be of blink kinematic analysis of review of video recording. Results would also be correlated with the Blepharospasm Severity Disability Index, Modified CDQ-24 scale and Jankovic Rating Scale. To assess any change in anxiety that might be relevant to therapeutic effect, the anxiety scale GAD-7 survey will also be administered and correlated with the results. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone.
OTC NCT04423341 Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Enrolling by invitation Silkiss Eye Surgery Phase 2/Phase 3 2020-05-20 The planned study is a prospective analysis of non-psychoactive Cannabidiol (without THC) as an adjunctive therapy for blepharospasm in a masked double cross-over study. This prospective study is a follow-up to a retrospective study completed by the researchers using over-the-counter, self purchased CBD. This study will use FDA approved Cannabidiol medication, Epidiolex, directly from GW pharmaceuticals, rather than self-purchased CBD from the internet. Additionally, patients will undergo EEG monitoring via a Blink-EEG protocol for objective data measurements of changes induced by CBD in Blepharospasm patients. Independent second measures will be of blink kinematic analysis of review of video recording. Results would also be correlated with the Blepharospasm Severity Disability Index, Modified CDQ-24 scale and Jankovic Rating Scale. To assess any change in anxiety that might be relevant to therapeutic effect, the anxiety scale GAD-7 survey will also be administered and correlated with the results. This study will attempt to codify the data and quantify if adjunctive CBD therapy improves those areas compared to botulinum injection alone.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Cannabidiol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00241592 Vaporization as a Smokeless Cannabis Delivery System Completed University of California, San Francisco Phase 1 2004-08-01 A study to evaluate the use of a vaporization system as a smokeless delivery system for inhaled marijuana.
NCT00241592 Vaporization as a Smokeless Cannabis Delivery System Completed Center for Medicinal Cannabis Research Phase 1 2004-08-01 A study to evaluate the use of a vaporization system as a smokeless delivery system for inhaled marijuana.
NCT00309413 A Clinical Trial on the Antipsychotic Properties of Cannabidiol Completed Coordinating Centre for Clinical Trials Cologne Phase 2 2006-03-01 The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study.
NCT00309413 A Clinical Trial on the Antipsychotic Properties of Cannabidiol Completed Stanley Medical Research Institute Phase 2 2006-03-01 The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study.
NCT00309413 A Clinical Trial on the Antipsychotic Properties of Cannabidiol Completed University of Cologne Phase 2 2006-03-01 The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-controlled, randomized double-blind study.
NCT00397605 Cannabinoids in Bipolar Affective Disorder Withdrawn Vancouver General Hospital N/A 2006-11-01 Some people with bipolar disorder who use cannabis (marijuana) claim that it eases the symptoms of depression and mania. There are many chemicals (called cannabinoids) found in cannabis but two particular ones appear to have medicinal (therapeutic) effects. These two compounds are: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These cannabinoids appear to have mood, anxiety, and sedative effects as well as have antipsychotic and anticonvulsant properties. This study will try to find out if these cannabinoids can be of benefit as an add-on treatment in bipolar disorder and what effects it has on thinking power and memory.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cannabidiol

Condition Name

Condition Name for Cannabidiol
Intervention Trials
Epilepsy 17
Schizophrenia 9
Dravet Syndrome 7
Anxiety 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cannabidiol
Intervention Trials
Marijuana Abuse 19
Syndrome 19
Epilepsy 14
Disease 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cannabidiol

Trials by Country

Trials by Country for Cannabidiol
Location Trials
United States 163
Canada 20
Germany 16
Israel 15
United Kingdom 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cannabidiol
Location Trials
California 17
New York 16
Massachusetts 10
Maryland 10
Pennsylvania 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cannabidiol

Clinical Trial Phase

Clinical Trial Phase for Cannabidiol
Clinical Trial Phase Trials
Phase 4 3
Phase 3 27
Phase 2/Phase 3 12
[disabled in preview] 122
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cannabidiol
Clinical Trial Phase Trials
Not yet recruiting 86
Recruiting 42
Completed 29
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cannabidiol

Sponsor Name

Sponsor Name for Cannabidiol
Sponsor Trials
GW Research Ltd 23
GW Pharmaceuticals Ltd. 13
INSYS Therapeutics Inc 12
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cannabidiol
Sponsor Trials
Other 192
Industry 79
NIH 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Dow
Boehringer Ingelheim
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.